# US 2026/0098067 A1 · Use of a small native peptide activator of serca pump for treatment of heart failure and other disorders characterized by cytosolic calcium overload

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098067 A1
- Document ID: US20260098067A1
- Status: Published application
- Kind: A1
- Application number: 19/229,899
- Filed: 2025-06-05
- Published: 2026-04-09
- Earliest claimed: 2016-04-19
- Assignees: Board of Regents, The University of Texas System
- Applicants: The Board of Regents of The University of Texas System
- Inventors: Eric N. OLSON; Rhonda S. BASSEL-DUBY; Catherine A. MAKAREWICH; Benjamin R. NELSON
- Web page: https://patentgrep.com/patent/US20260098067A1

## CPC

- C07K 14/47: from mammals
- A61K 38/1709: {from mammals}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.

## Claims

### Claim 1

A method of treating a muscle disorder or a cardiovascular disease or disorder in a subject in need thereof, comprising administering to the subject a polynucleotide sequence encoding a human Dwarf open reading frame (DWORF) polypeptide.

### Claim 2 (depends on 1)

The method of claim 1, wherein the disease or disorder is a disease associated with cytosolic calcium overload, or symptom thereof.

### Claim 3 (depends on 1)

The method of claim 1, wherein the muscle disorder is muscular dystrophy.

### Claim 4 (depends on 1)

The method of claim 1, wherein the cardiovascular disease or disorder is cardiomyopathy, heart failure, or myocardial infarction.

### Claim 5 (depends on 4)

The method of claim 4, wherein the cardiomyopathy is dilated cardiomyopathy.

### Claim 6 (depends on 1)

The method of claim 1, wherein the DWORF polypeptide has at least 80%, 85%, 90%, or 95% identity with the amino acid sequence of SEQ ID NO: 3.

### Claim 7 (depends on 1)

The method of claim 1, wherein the DWORF polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

### Claim 8 (depends on 1)

The method of claim 1, wherein the DWORF polypeptide consists of the amino acid sequence of SEQ ID NO: 3.

### Claim 9 (depends on 1)

The method of claim 1, wherein the polynucleotide sequence has at least 80% identity to the nucleic acid sequence of SEQ ID NO: 4.

### Claim 10 (depends on 1)

The method of claim 1, wherein the polynucleotide sequence comprises the nucleic acid sequence of SEQ ID NO: 4.

### Claim 11 (depends on 1)

The method of claim 1, wherein the polynucleotide sequence consists of the nucleic acid sequence of SEQ ID NO: 4.

### Claim 12 (depends on 1)

The method of claim 1, wherein the polynucleotide sequence is operatively linked to a heterologous muscle-specific or cardiac-specific promoter.

### Claim 13 (depends on 12)

The method of claim 12, wherein the heterologous cardiac-specific promoter is a cardiomyocyte-specific α-myosin heavy chain (αMHC) promoter.

### Claim 14 (depends on 1)

The method of claim 1, wherein the subject is a mammal.

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 16 (depends on 1)

The method of claim 1, wherein the method leads to expression of the DWORF polypeptide in cardiomyocytes of the subject.

### Claim 17 (depends on 1)

The method of claim 1, wherein the method:
a) leads to an enhancement of SERCA activity; and/or
b) improves one or more measures of cardiac function, optionally ejection fraction, fraction shortening and/or left ventricular internal dimension (LVID), and/or fibrosis.

### Claim 18 (depends on 1)

The method of claim 1, wherein the administering is systemic administration.

### Claim 19 (depends on 1)

A method of treating a muscle disorder or a cardiovascular disease or disorder in a subject in need thereof, comprising administering to the subject a vector comprising the polynucleotide sequence of claim 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the vector is an adeno-associated viral (AAV) vector.
